Pharmacological interactions with darunavir;Interacciones medicamentosas de darunavir

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 10, 2008, Pages 43-50

  Moltó, José ^a,b   Valle, Marta ^b,c   Clotet, Bonaventura ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Darunavir; Drug drug interactions

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; ATORVASTATIN; CLARITHROMYCIN; CYTOCHROME P450 3A4; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; DIGOXIN; EFAVIRENZ; ENFUVIRTIDE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETRAVIRINE; INDINAVIR; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; METHADONE; NEVIRAPINE; OMEPRAZOLE; PAROXETINE; PRAVASTATIN; RANITIDINE; RITONAVIR PLUS SAQUINAVIR; SERTRALINE; SILDENAFIL; TENOFOVIR;

AREA UNDER THE CURVE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; VIROLOGY;

EID: 75849131389     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76553-4     Document Type: Article

References (27)

1. S. De Meyer, H. Azijn, and D. Surleraux TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitorresistant viruses, including a broad range of clinical isolates Antimicrob Agents Chemother 49 2005 2314 2321 (Pubitemid 40734460)
2. B. Clotet, N. Bellos, and J.M. Molina Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials Lancet 369 2007 1169 1178 (Pubitemid 46541620)
3. J.V. Madruga, D. Berger, and M. McMurchie Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial Lancet 370 2007 49 58 (Pubitemid 47023100)
4. R. Ortiz, E. DeJesus, H. Khanlou, E. Veronin, J. Van Lunzen, J. Andrade-Villanueva, et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48 AIDS 22 2008 1389 1397
5. PREZISTA® (darunavir). Ficha técnica. Disponible en: http://www.emea.europa.eu/humandocs/Humans/EPAR/prezista/prezista.htm
6. V. Sekar, S. Spinosa-Guzmán, E. Lefebvre, et al. Cinical Pharmacology of TMC114 - a new HIV protease inhibitor 16th Internacional AIDS Conference Toronto 2006 (abstract TUPE0083)
7. V. Sekar, S. De Meyer, T. Vangeneudgden, et al. Pharmacokinetic/ pharmacodynamic (PK/PD) analyses of TMC114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients 13th Conference on Retroviruses and Opportunistic Infections Denver 2006 (abstract J-121)
8. V. Sekar, E. Lefebvre, S. Spinosa-Guzmán, et al. Pharmacokinetic interaction between the HIV protease inhibitors TMC114 and saquinavir, in the presence of low-dose of ritonavir 44th Annual Meeting of the Infectious Diseases Society of America Toronto 2006 (abstract 959)
9. V. Sekar, E. Lefebvre, G. Boogaerts, et al. Pharmacokinetic interaction between the protease inhibitors TMC114 and lopinavir/ritonavir 46th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco 2006 (abstract A-367)
10. V. Sekar, T. De Marez, S. Spinosa-Guzmán, et al. Pharmacokinetic interaction between TMC114/ritonavir and atazanavir in healthy volunteers 10th European AIDS Conference Dublin 2005 (abstract PE4.3/4)
11. V. Sekar, M. De Pauwn, and K. Marien Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers Antivir Ther 12 2007 509 514 (Pubitemid 47041149)
12. V. Sekar, E. Lefevbre, K. Marien, et al. Pharmacokinetic interaction between the antirretroviral agents TMC114 and nevirapine, in the presence of low-dose ritonavir 44th Annual Meeting of the Infectious Diseases Society of America Toronto 2006 (abstract 956)
13. M. Boffito, A. Winston, C. Fletcher, et al. Pharmacokinetics (PK) and antiretroviral (ARV) response to TMC114/r and TMC125 combination in patients with high level viral resistance 13th Conference on Retroviruses and Opportunistic Infections Denver 2006 (abstract 575c)
14. R. Hoetelmans, K. Mariën, and M. De Pauw Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers Br J Clin Pharmacol 64 2007 655 661 (Pubitemid 47568821)
15. V. Sekar, S. Spinosa-Guzmán, E. De Paepe, et al. Pharmacokinetic interaction trial between darunavir in combination with low-dose of ritonavir and didanosine 4th IAS Conference on HIV Patogénesis, Treatment and Prevention Sydney 2007 (abstract WEPEB012)
16. V. Sekar, E. De Paepe, T. Vangeneugden, et al. Absence of an interaction between the potent HIV protease inhibitor TMC114 and the fusion inhibitor enfuvirtide in the POWER 3 analysis 7th International Workshop on Clinical Pharmacology of HIV Therapy Lisboa 2006 (abstract 54)
17. S. Abel, G. Ridgeway, J. Hamlin, et al. An open, randomised, 2-way crossover study to investigate the effect of darunavir/ritonavir on the pharmacokinetics of Maraviroc in healthy subjects 8th International Workshop on Clinical Pharmacology of HIV Therapy Budapest 2007 (abstract 55)
18. A. Mathias, G. Shen, J. Enejosa, et al. Lack of pharmacokinetic interaction between ritonavir-boosted GS-9137(elvitegravir) and darunavir/r 4th IAS Conference on HIV Pathogenesis and Treatment Sydney 2007 (abstract TUPDB03)
19. V. Sekar, S. Guzmán, M. De Pauwn, et al. The pharmacokinetic interaction between clarithromycin and TMC114/ritonavir in healthy subjects The 2006 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics Baltimore 2006 (abstract PI-61)
20. V. Sekar, E. Lefevbre, M. De Pauwn, et al. Pharmacokinetic interaction between TMC114 and ketoconazole, in the absence and presence of low-dose ritonavir 44th Annual Meeting of the Infectious Diseases Society of America Toronto 2006 (abstract P960)
21. V.J. Sekar, S. Spinosa-Guzmán, K. Marien, et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin 8th International Workshop on Pharmacology of HIV Therapy Budapest 2007 (abstract 55)
22. R. Hoetelmans, A. Lasure, A. Koester, et al. The effect of TMC114, a potent next-generation HIV protease inhibitor, with low-dose ritonavir on atorvastatin pharmacokinetics 44th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington DC 2005 (abstract H-865)
23. V. Sekar, E. Lefebvre, S. Spinosa-Guzmán, et al. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and TMC114, a new protease inhibitor 46th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco 2006 (abstract A-0368)
24. V. Sekar, E. Lefebvre, and E. De Paepe Pharmacokinetic interaction of darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers Antimicrob Agents Chemother 51 2007 958 961 (Pubitemid 46355280)
25. V. Sekar, M. Malt, E. De Paepe, et al. Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and methadone 8th International Congress on Drug Therapy in HIV Infection Glasgow 2006 (abstract P294)
26. V. Sekar, E. Lefebvre, T. De Marez, et al. Pharmacokinetic interaction between TMC114, a new protease inhibitor and sildenafil 46th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco 2006 (abstract A-0369)
27. V. Sekar, E. De Paepe, T. De Marez, et al. Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and the selective serotonin reuptake inhibitors (SSRIs), paroxetine and sertraline 8th Internacional Congress on Drug Therapy in HIV Infection Glasgow 2006 (abstract P295)